Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF 322.30
+1.60 (0.50%)
Inactive · Last trade price on Mar 16, 2026
Roche Holding AG Revenue
In the year 2025, Roche Holding AG had annual revenue of 63.36B CHF with 1.54% growth. Roche Holding AG had revenue of 31.51B in the half year ending December 31, 2025, with 5.64% growth.
Revenue
63.36B
Revenue Growth
+1.54%
P/S Ratio
4.06
Revenue / Employee
613.62K
Employees
103,249
Market Cap
257.46B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRoche Holding AG News
- 1 hour ago - Roche rapidly develops a PCR test for Ebola within six days as rare Bundibugyo virus drives urgent need for detection - PRNewsWire
- 2 hours ago - Roche chairman likens US tariff policy to 'blackmail' - Reuters
- 2 days ago - FDA Grants Priority Review For Roche's NDA For Giredestrant In Breast Cancer - Nasdaq
- 2 days ago - Roche Announces FDA's Filing Acceptance Under Priority Review For Giredestrant - Nasdaq
- 2 days ago - FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting - Business Wire
- 2 days ago - FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting - GlobeNewsWire
- 3 days ago - Genentech Presents Updated Clinical Results Of Enicepatide And Petrelintide At ADA 2026 - Nasdaq
- 3 days ago - Louth GAA FL Division 2 Round-up: Walsh in sizzling form for Fechins as Roche sit top - Independent Ireland